Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed in Stage IIIB/IV Bronchioloalveolar Carcinoma
NCT00265785Phase 2Terminated
- Sponsor
- SWOG Cancer Research Network
- Start
- Jul 2006
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in bronchioloalveolar carcinoma (BAC), sponsored by SWOG Cancer Research Network. Primary endpoint: Overall Survival at 3 years. Started Jul 2006; status: terminated.
02
Drugs
pemetrexed
03
Conditions
bronchioloalveolar carcinoma (BAC)
Beyond the preview
Go deeper on NCT00265785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00265785.